2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/08/17Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Nov. 8, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming investor conferences: The Stifel Nicolaus 2017 Healthcare Conference on Tuesday, November 14, at 10:15 a.m. ET in New York City, NY, USA The Jefferies 2017 London ... 
Printer Friendly Version
11/07/17Verastem Reports Third Quarter 2017 Financial Results
BOSTON--(BUSINESS WIRE)--Nov. 7, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the third quarter ended September 30, 2017 and provided an overview of certain corporate developments and plans. “The third quarter was a pivotal time for Verastem with the announcement of positive top-line data from the pivotal... 
Printer Friendly Version
11/01/17Verastem Announces Data from Phase 3 DUO Study Selected for Oral Presentation at the American Society of Hematology 2017 Annual Meeting
Four Abstracts Selected, Including Two Oral Presentations BOSTON--(BUSINESS WIRE)--Nov. 1, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that four abstracts have been selected for presentation, including two oral presentations, at the upcoming American Society of Hematology (ASH) 2017 Annual Meeting being held December 9-12, 2017 in ... 
Printer Friendly Version
10/31/17Verastem Announces Regulatory Strategy for Duvelisib New Drug Application Following Guidance from FDA
Company Plans to Submit a Single NDA Requesting Full Approval of Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Accelerated Approval for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma Company Plans to Submit NDA for Duvelisib During First Quarter of 2018 BOSTON--(BUSINESS WIRE)--Oct. 31, 2017-- Verastem, Inc. (NASDAQ: VSTM), focu... 
Printer Friendly Version
10/17/17Verastem Pays Milestone Payment to Infinity Pharmaceuticals
BOSTON, Mass.--(BUSINESS WIRE)--Oct. 17, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced payment of a $6 million milestone to Infinity Pharmaceuticals, Inc., representing the first milestone under the duvelisib license agreement between Verastem and Infinity. This milestone is based on the achievement of positive top-line results from t... 
Printer Friendly Version
10/11/17Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer
BOSTON--(BUSINESS WIRE)--Oct. 11, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of NgocDiep Le, MD, PhD, as Chief Medical Officer. Dr. Le will be responsible for overseeing the development strategy and activities for Verastem’s core assets, duvelisib and defactinib. “Diep is a highly accomplished physician-scie... 
Printer Friendly Version
09/22/17Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Sep. 22, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25th at 8:35 a.m. ET at the InterContinental New York Barclay Hotel in New York. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. ... 
Printer Friendly Version
09/06/17Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma
Duvelisib Receives Fast Track Designation from FDA in PTCL; Company to Initiate a Phase 2 Clinical Trial by Year End 2017 Former Chief Marketing Officer, Lilly Oncology, Brian Stuglik Joins the Company’s Board of Directors Conference Call Scheduled for Today at 8:00 AM ET BOSTON--(BUSINESS WIRE)--Sep. 6, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life ... 
Printer Friendly Version
09/06/17Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The Primary Outcome of Progression Free Survival (PFS) via Independent Review Committee (IRC) in the Intent to Treat (ITT) Population Significantly Favored Duvelisib Monotherapy Over Ofatumumab (Median PFS of 13.3 versus 9.9 Months, Respectively; Hazard Ratio (HR) of 0.52, p<0.0001) Similar Efficacy Benefit for Duvelisib Monotherapy Over Ofatumumab for Patients with 17p Deletion (Median PFS of 12.7 versus 9.0 Months, Respectively; HR of... 
Printer Friendly Version
08/08/17Verastem Reports Second Quarter 2017 Financial Results
Company Expects to Report Top-line Data from Phase 3 DUO™ Study in Late Summer 2017 BOSTON--(BUSINESS WIRE)--Aug. 8, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the second quarter ended June 30, 2017 and provided an overview of certain corporate developments. “The second quarter of 2017 was marked b... 
Printer Friendly Version
07/25/17Verastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer
Preclinical Data Supportive of Ongoing Clinical Collaboration Trials Evaluating FAK Inhibition in Combination with Chemotherapeutic and Immunotherapeutic Agents BOSTON--(BUSINESS WIRE)--Jul. 25, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced scientific findings from studies evaluating focal adhesion kinase (FAK) inhibition in precl... 
Printer Friendly Version
07/11/17Verastem Names Julie B. Feder as Chief Financial Officer
BOSTON--(BUSINESS WIRE)--Jul. 11, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Julie B. Feder as Chief Financial Officer. “Julie is an accomplished financial professional with invaluable leadership experience in healthcare, having served as Chief Financial Officer of the Clinton Health Access Initiative and... 
Printer Friendly Version
06/24/17Verastem Reports Phase 2 Long-Term Follow-Up Data for Duvelisib in Patients with Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma at the 22nd Congress of the European Hematology Association
43% ORR per IRC in Patients with Double-Refractory Follicular Lymphoma 68% ORR per IRC in Patients with Double-Refractory Small Lymphocytic Lymphoma Duvelisib Remains Well Tolerated in Long-Term Follow Up BOSTON--(BUSINESS WIRE)--Jun. 24, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of long-term ... 
Printer Friendly Version
06/07/17Verastem to Present Long-Term Follow-Up Data from the DYNAMO™ Study at the 14th International Conference on Malignant Lymphoma
Duvelisib Monotherapy Treatment Demonstrates 47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma 88% of Patients had a Reduction in the Size of Target Lymph Nodes Duvelisib Remains Well-Tolerated in Long-Term Follow Up BOSTON--(BUSINESS WIRE)--Jun. 7, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announc... 
Printer Friendly Version
05/31/17Verastem to Present at the Jefferies 2017 Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--May 31, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the company will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:00 a.m. ET at the Grand Hyatt in New York City. A live audio webcast of the presentation will be available on the company’s website at www.vera... 
Printer Friendly Version
05/18/17Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association
Abstract Highlighting Long-Term Follow Up Data from the DYNAMO® Study of Duvelisib in Patients with Double-Refractory Follicular Lymphoma Selected for Oral Presentation BOSTON--(BUSINESS WIRE)--May 18, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced an abstract featuring long-term follow up data from the DYNAMO® study evaluating duv... 
Printer Friendly Version
05/10/17Verastem Reports First Quarter 2017 Financial Results
BOSTON--(BUSINESS WIRE)--May 10, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the first quarter ended March 31, 2017 and provided an overview of certain corporate developments. “Following the presentation of positive data from the DYNAMO™ study of duvelisib in indolent non-Hodgkins Lymphoma (iNHL) at the Americ... 
Printer Friendly Version
05/03/17Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma
BOSTON--(BUSINESS WIRE)--May 3, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that an abstract describing long term follow-up data from the DYNAMO® study has been selected for oral presentation at the 14th International Conference on Malignant Lymphoma (ICML) being held June 14-17, 2017 in Lugano, Switzerland. DYNAMO is a Phase 2 clinical tr... 
Printer Friendly Version
05/02/17Verastem Appoints Eric K. Rowinsky to the Board of Directors
BOSTON--(BUSINESS WIRE)--May 2, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Eric K. Rowinsky, MD to its Board of Directors. Dr. Rowinsky brings to Verastem nearly 30 years of experience in the development of cancer treatments, such as cetuximab (Erbitux) when he was Chief Medical Officer of ImClone Systems... 
Printer Friendly Version
04/03/17Verastem to Present at the 16th Annual Needham Healthcare Conference
BOSTON--(BUSINESS WIRE)--Apr. 3, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 3:00 p.m. ET at The Westin Grand Central in New York City. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived presentat... 
Printer Friendly Version
04/02/17Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting
BOSTON--(BUSINESS WIRE)--Apr. 2, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of data for its lead focal adhesion kinase (FAK) inhibitor, defactinib, by the Company’s scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine, Division of Oncology, Department of Immunology, Washington University School of Medicine in St. Louis, at the 2017 ... 
Printer Friendly Version
03/23/17Verastem Reports Year-End 2016 Financial Results
BOSTON--(BUSINESS WIRE)--Mar. 23, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2016, and also provided an overview of certain corporate developments. “2016 was a year of significant achievement for Verastem with the in-licensing of duvelisib, a late-stage, clinical product candidate with broad potential across B-cell and T... 
Printer Friendly Version
03/16/17Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
BOSTON--(BUSINESS WIRE)--Mar. 16, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 23, 2017 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2016. The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315... 
Printer Friendly Version
03/15/17Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Mar. 15, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21st at 2:10 p.m. ET at the Westin Grand Central in New York City. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived pre... 
Printer Friendly Version
03/07/17Verastem to Present at the 29th Annual ROTH Conference
BOSTON--(BUSINESS WIRE)--Mar. 7, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 29th Annual ROTH Conference on Monday, March 13th at 4:00 p.m. PT at the Ritz Carlton in Dana Point, CA. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived presentation will be available for 9... 
Printer Friendly Version
02/07/17Verastem to Present at 19th Annual BIO CEO & Investor Conference
BOSTON--(BUSINESS WIRE)--Feb. 7, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th at 9:00 a.m. ET at the Waldorf Astoria Hotel in New York City. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived ... 
Printer Friendly Version
01/26/17Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer
Phase 1/2 Study Expected to Enroll Approximately 100 Patients at up to 15 sites in the U.S. BOSTON--(BUSINESS WIRE)--Jan. 26, 2017-- Verastem, Inc., (NASDAQ:VSTM) today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s defactinib**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanc... 
Printer Friendly Version
01/19/17Verastem Announces Executive Leadership Appointments and Changes
Hagop Youssoufian, MSc, MD Named Head of Hematology and Oncology Development; Greg I. Berk, MD to Transition to Senior Advisor and Member of Clinical and Scientific Advisory Board Lori Kunkel, MD and Edmund J. Pezalla, MD, MPH Appointed to Clinical and Scientific Advisory Board Michael Ferraresso to Join the Company as Vice President, Commercial Operations BOSTON--(BUSINESS WIRE)--Jan. 19, 2017-- Verastem, Inc. (NASDAQ: ... 
Printer Friendly Version